At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 90 enrolled
Drug / intervention
Sitagliptin +2 moredrug
Likely dose
Sitagliptin 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Controlled Study of Dipeptidyl Peptidase-4 (DPP4) Inhibitor (Sitagliptin) Therapy in the Inpatient Management of Patients With Type 2 Diabetes
In Brief
A Phase 4 clinical trial evaluating Sitagliptin, glargine, and 1 other intervention for Type 2 Diabetes Mellitus and 2 related conditions. Completed, enrolled 90 participants across 2 sites.
Detailed Summary
The study is a multicenter, prospective, open-label, randomized pilot study to investigate the safety and efficacy of sitagliptin (Januvia) for the inpatient management of type 2 diabetes (T2D) in general medicine and surgery patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Enrollment StartAug 2011
Primary CompletionMay 2012
Study CompletionJun 2012
TodayJul 2026
First PostedJun 22, 2011
Enrollment StartAug 1, 2011
Primary CompletionMay 1, 2012
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.0 years ago
Interventions
Sitagliptindrug
Sitagliptin 50-100mg po once daily
glarginedrug
glargine once daily
lisprodrug
lispro before meals